A dysmorphic feature is an abnormal difference in body structure. It can be an isolated finding in an otherwise normal individual, or it can be related to a congenital disorder, genetic syndrome or birth defect. Dysmorphology is the study of dysmorphic features, their origins and proper nomenclature. One of the key challenges in identifying and describing dysmorphic features is the use and understanding of specific terms between different individuals. Clinical geneticists and pediatricians
are usually those most closely involved with the identification and description of dysmorphic features, as most are apparent during childhood. Dysmorphic features can vary from isolated, mild anomalies such as clinodactyly or synophrys to severe congenital anomalies, such as heart defects and holoprosencephaly. In some cases, dysmorphic features are part of a larger clinical picture, sometimes known as a sequence, syndrome or association. Recognizing the patterns of dysmorphic features is an important part of a geneticists diagnostic process, as many genetic disease present with a common collection of features. There are several commercially available databases that allow clinicians to input their observed features in a patient to generate a differential diagnosis. These databases are not infallible, as they require on the clinician to provide their own experience, particularly when the observed clinical features are general. A male child with short stature and hypertelorism could have several different disorders, as these findings are not highly specific.
Ipratropium bromide/salbutamol, is sold under the brand name DuoNeb as a nebulized solution, is a combination medication used to treat chronic obstructive pulmonary disease (COPD). It contains ipratropium (an anticholinergic) and salbutamol (albuterol, a β2-adrenergic agonist).Common side effects include sore throat, muscle cramps, and nausea. Other side effects may include bronchospasm, allergic reactions, and upper respiratory tract infections. Safety in pregnancy is unclear. Each medication typically decreases bronchospasm and does so via different mechanisms.The combination was approved for medical use in the United States in 1996. It is available as a generic medication. In 2019, it was the 151st most commonly prescribed medication in the United States, with more than 4 million prescriptions. Society and culture
Since Combivent contains a chlorofluorocarbon-based propellant, its use was discontinued in 2013 in the United States and other countries. This was because Chloroflourocarbons (CFC) are attributed to depletion of the ozone layer. References
External links
DailyMed
Consumer Medication Information from PubMed Archived 2012-12-03 at the Wayback Machine
Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. National Heart, Lung, and Blood Institute. 2007.